# Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer

> **NCT04217057** · PHASE1 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 11 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** 64Cu-DOTA-ECL1i

## Key facts

- **NCT ID:** NCT04217057
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-07
- **Primary completion:** 2023-02-07
- **Final completion:** 2023-02-07
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Insufficient funding/staff
- **Last updated:** 2024-11-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04217057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04217057, "Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04217057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*